How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,774 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. (PubMed)

Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial or venous thrombosis (or both) and/or pregnancy morbidity in association with the presence of antiphospholipid antibodies. The prevalence is estimated at 40 to 50 cases per 100,000 people. The most common sites of thrombosis are cerebral arteries and deep veins

Full Text available with Trip Pro

2017 Cochrane

22. Recommendations for the prevention of pregnancy-associated venous thromboembolism

impact of maternal obesity on obstetric practice , Australian and New Zealand Journal of Obstetrics and Gynaecology , 52 , 5 , (409-411) , (2012) . Emily Bain, Agnes Wilson, Rebecca Tooher, Simon Gates, Lucy-Jane Davis and Philippa Middleton , Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period , Cochrane Database of Systematic Reviews , 10.1002/14651858.CD001689.pub3 , (2014) . Ida Martinelli, Valerio De Stefano and Pier M. Mannucci , Inherited risk factors (...) Recommendations for the prevention of pregnancy-associated venous thromboembolism Recommendations for the prevention of pregnancy‐associated venous thromboembolism - McLINTOCK - 2012 - Australian and New Zealand Journal of Obstetrics and Gynaecology - Wiley Online Library Search within Search term Search term Opinion Recommendations for the prevention of pregnancy‐associated venous thromboembolism National Women’s Health, Auckland City Hospital, Grafton, Auckland, New Zealand Department

2012 Clinical Practice Guidelines Portal

23. An Analysis Into the Cause and Preventional Method of Thromboembolic Disease in Gynecological Surgery

An Analysis Into the Cause and Preventional Method of Thromboembolic Disease in Gynecological Surgery An Analysis Into the Cause and Preventional Method of Thromboembolic Disease in Gynecological Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. An Analysis Into the Cause and Preventional Method of Thromboembolic Disease in Gynecological Surgery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03644992 Recruitment

2018 Clinical Trials

24. A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery (SELECT) The safety and scientific validity of this study is the responsibility of the study sponsor

2018 Clinical Trials

25. Genital Haemorrhage in Woman of Childbearing Age Treated for Venous Thromboembolism Disease : Comparison According to Oral Anticoagulant and Impact on Quality of Life

Genital Haemorrhage in Woman of Childbearing Age Treated for Venous Thromboembolism Disease : Comparison According to Oral Anticoagulant and Impact on Quality of Life Genital Haemorrhage in Woman of Childbearing Age Treated for Venous Thromboembolism Disease : Comparison According to Oral Anticoagulant and Impact on Quality of Life - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms (...) x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Genital Haemorrhage in Woman of Childbearing Age Treated for Venous Thromboembolism Disease : Comparison According to Oral Anticoagulant and Impact on Quality of Life (GENB-OAB) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean

2018 Clinical Trials

26. Venous Thromboembolism Risk and Adequacy of Prophylaxis in High Risk Pregnancy in the Arabian Gulf (PubMed)

Venous Thromboembolism Risk and Adequacy of Prophylaxis in High Risk Pregnancy in the Arabian Gulf To estimate the prevalence of venous thromboembolism (VTE) risk factors in pregnancy and the proportion of pregnancies at risk of VTE that received the recommended prophylaxis according to the American College of Chest Physicians (ACCP) 2012 published guidelines in antenatal clinics in the Arabian Gulf.The evaluation of venous thromboembolism (EVE)-Risk project was a non-interventional, cross (...) (6.9%), thrombophilia (2.6%), immobilization (2.0%), sickle cell disease (2.8%) and previous VTE (1.6%). Only 8.3% (n=111) of the high risk patients were on the recommended VTE prophylaxis. Enoxaparin was used in 80% (n=89) of the cases followed by tinzaparin (4%; n=4). Antiplatelet agents were prescribed in 11% (n=149) of pregnant women. Of those on anticoagulants (n=111), 59% (n=66) were also co-prescribed antiplatelet agents. Side effects (mainly local bruising at the injection site) were

Full Text available with Trip Pro

2016 Current vascular pharmacology

27. Prevention of Peri-operative Venous Thromboembolism in Paedatric Patients

in approximately 10% Drugs Chemotherapy e.g. aspariginase Contraceptive pill (3 fold increase risk) Parenteral nutrition (may be line related) Immobility 25% cases with prolonged bed rest Pregnancy (2) 2 fold increase Congenital thrombophilia (3/4) Factor V Leiden Antithrombin III deficiency Protein C / S deficiency Increased F VIII Acquired Thrombophilia (3/4) Nephrotic syndrome Antiphospholipid syndrome Connective tissue disease Obesity (2) Increased incidence of VTE cardiac disease Congenital disease (...) , Trimarchi T, Beliveau J, Davis D. Thromboprophylaxis in a pediatric hospital: a patient-safety and quality-improvement initiative. Pediatrics. 2011 May;127(5):e1326-32. 16. Newall F, Wallace T, Crock C, Campbell J, Savoia H, Barnes C, et al. Venous thromboembolic disease: a single-centre case series study. J Paediatr Child Health. 2006 Dec;42(12):803–7. 17. Raffini L, Huang Y-S, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001

2017 Association of Paediatric Anaesthetists of Great Britain and Ireland

28. Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease

Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Time (...) of Treatment With LMWH in Cancer Patients With Thromboembolic Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03134820 Recruitment Status : Completed First Posted : May 1, 2017 Last Update Posted : May 1, 2017 Sponsor: Delos Clinical Information provided by (Responsible Party): Remedios Otero

2017 Clinical Trials

29. Sickle cell disease and venous thromboembolism in pregnancy and the puerperium.

Sickle cell disease and venous thromboembolism in pregnancy and the puerperium. Recent data strongly suggest an increased risk of venous thromboembolism in subjects with sickle cell disease and to a lesser extent, sickle cell trait. However, most studies have been retrospective, case-control or cross-sectional based on data obtained from administrative databases. More data from adequately powered prospective studies that include matched controls are needed to definitely establish the link (...) between venous thromboembolism during pregnancy and sickle hemoglobin disorders. Similarly, there remains a need for properly designed randomized control trials to establish the safety of various hormonal contraceptive methods in women with sickle cell disorders. © 2015 Elsevier Ltd. All rights reserved.

2015 Thrombosis research

30. A case of successfully managed pregnancy in a patient with complex cyanotic congenital heart disease (PubMed)

A case of successfully managed pregnancy in a patient with complex cyanotic congenital heart disease Medical advances have increased survival of patients with congenital heart disease. However, cardiac disease in pregnancy carries significant maternal and fetal risks, posing enormous challenges to obstetricians. Cyanotic congenital heart disease is associated with maternal complications such as arrhythmias, thromboembolic events and death. Fetal complications include small for gestational age (...) , miscarriage and prematurity. Cyanotic congenital heart disease patients who continue their pregnancies require holistic multidisciplinary team care with early and coordinated planning for delivery. Management of such patients include early counseling regarding pregnancy-associated risks, close monitoring of their cardiac function and regular scanning for fetal assessment. Choice of anesthesia for these patients requires meticulous planning to achieve a favorable balance between systemic and pulmonary

Full Text available with Trip Pro

2016 Obstetric medicine

31. Obesity in Pregnancy

should be advised that they are at risk for medical complications such as cardiac disease, pulmonary disease, gestational hypertension, gestational diabetes, and obstructive sleep apnea. Regular exercise during pregnancy may help to reduce some of these risks (II-2B). 5. Obese women should be advised that their fetus is at an increased risk of congenital abnormalities, and appropriate screening should be done (II-2B). 6. Obstetric care providers should take BMI into consideration when arranging (...) Obesity in Pregnancy No. 239-Obesity in Pregnancy - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 40, Issue 8, Pages e630–e639 No. 239-Obesity in Pregnancy x Gregory A.L. Davies , MD Kingston, ON x Cynthia Maxwell , MD Toronto, ON x Lynne McLeod , MD Halifax, NS No. 239, February 2010 (Reaffirmed August 2018) DOI: To view the full text, please login as a subscribed user or . Click to view the full text

2018 Society of Obstetricians and Gynaecologists of Canada

32. Pregnancy

-eclampsia. Anaemia. Down's syndrome. Haemoglobinopathies (sickle cell disease and thalassaemia 2016 3. Management of Cardiovascular Diseases during Pregnancy We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy | European Heart Journal | Oxford Academic Search Account Menu Menu Navbar Search (...) Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close (...) mobile search navigation Article navigation 07 September 2018 Article Contents Article Navigation 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy Vera Regitz-Zagrosek Chairperson Corresponding authors. Vera Regitz-Zagrosek, Charité Universitaetsmedizin Berlin, Institute for Gender in Medicine, CCR, DZHK, partner site Berlin, Hessische Str 3-4, 10115 Berlin, Germany

2018 Trip Latest and Greatest

33. What Is the Best Imaging Study to Rule Out Pulmonary Embolism in Pregnancy? (SRS diagnosis)

What Is the Best Imaging Study to Rule Out Pulmonary Embolism in Pregnancy? (SRS diagnosis) What Is the Best Imaging Study to Rule Out Pulmonary Embolism in Pregnancy? TAKE-HOME MESSAGE Both computed tomography (CT) pulmonary angiography and lung scintigraphy (ie, ventilation-perfusion scan) are appropriate imaging options for exclusion of pulmonary embolism during pregnancy. EBEM Commentators Latha Ganti, MD, MBA David Lebowitz, MD Department of Clinical Sciences University of Central Florida (...) College of Medicine Orlando, FL Jestin N. Carlson, MD, MS, and Alan Jones, MD, serve as editors of the SRS series. Editor’s Note: This is a clinical synopsis, a regular feature of the Annals’ Systematic Review Snapshot (SRS) series. The source for this systematic review snapshot is: van Mens TE, Scheres LJJ, de Jong PG, et al. Imaging for theexclusion of pulmonary embolism in pregnancy. Cochrane Database Syst Rev. 2017;1:CD011053. Results Summary of results for the diagnosis of pulmonary embolism

2018 Annals of Emergency Medicine Systematic Review Snapshots

34. Care of Women with Obesity in Pregnancy

. Reducing the Risk of Venous Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management. Green-top Guideline No. 37b. London: RCOG; 2015. 100. Ismail SK, Norris L, O’Shea S, Higgins JR. Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women. Thromb Res 2014;134:234–9. 101. Overcash RT, Somers AT, LaCoursiere DY. Enoxaparin dosing after cesarean delivery in morbidly obese women. Obstet Gynecol 2015;125:1371–6. 102. Molyneaux E, Poston L (...) College of Obstetricians and GynaecologistsWhat speci?c risk assessments are required for prevention of pressure sores? Women with a booking BMI 40 kg/m 2 or greater should have a documented risk assessment in the third trimester of pregnancy by an appropriately quali?ed professional to consider tissue viability issues. This should involve the use of a validated scale to support clinical judgement. D Special considerations for screening, diagnosis and management of maternal disease in women

2018 Royal College of Obstetricians and Gynaecologists

35. Cancer-related Thromboembolic Disease

Cancer-related Thromboembolic Disease Cancer-related Thromboembolic Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cancer-related Thromboembolic Disease (PROSPECT) The safety and scientific (...) (Visit 4) and 12-month (or at the end of trial - Visit 5) visits. Patients eventually undergoing second-line chemotherapy during the course of the follow-up will remain on study. The study will document all cases of symptomatic thromboembolic events together with the relevant diagnostic work-up. Condition or disease Intervention/treatment Phase Adenocarcinoma Other: Thrombin Generation Assay Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical

2016 Clinical Trials

36. ABO Blood Group and Risk of Thromboembolic and Arterial Disease: A Study of 1.5 Million Blood Donors. (PubMed)

ABO Blood Group and Risk of Thromboembolic and Arterial Disease: A Study of 1.5 Million Blood Donors. ABO blood groups have been shown to be associated with increased risks of venous thromboembolic and arterial disease. However, the reported magnitude of this association is inconsistent and is based on evidence from small-scale studies.We used the SCANDAT2 (Scandinavian Donations and Transfusions) database of blood donors linked with other nationwide health data registers to investigate (...) , non-O blood groups were associated with higher incidence of both venous and arterial thromboembolic events. The highest rate ratios were observed for pregnancy-related venous thromboembolism (incidence rate ratio, 2.22; 95% confidence interval, 1.77-2.79), deep vein thrombosis (incidence rate ratio, 1.92; 95% confidence interval, 1.80-2.05), and pulmonary embolism (incidence rate ratio, 1.80; 95% confidence interval, 1.71-1.88).In this healthy population of blood donors, non-O blood groups explain

Full Text available with Trip Pro

2016 Circulation

37. The Birth Control Pill, Thromboembolic Disease, Science and the Media: A Historical Review of the Relationship. (PubMed)

The Birth Control Pill, Thromboembolic Disease, Science and the Media: A Historical Review of the Relationship. The introduction of the birth control pill (the Pill) in 1960 revolutionized the options for contraception, sparking vibrant discussion in the scientific and social science literature and in the media. Much attention focused on issues of women's rights, including ethics and personal choice. But the Pill also introduced new questions about risk. Shortly after its introduction, the risk (...) of thromboembolic disease was recognized [1]. After more than half a century, controversies about the relationship between the Pill and thromboembolic disease have persisted. The scientific and media communities have been active in the discussion, debate and delivery of information about this risk. Scientific and public attention to thromboembolism and the Pill has had dramatic consequences, both good and bad. The spotlight on risk has helped to change norms regarding the public's right to know and assess

2016 Contraception

38. Maternal, pregnancy and neonatal outcomes following IVF pregnancies

19: Incidence of thromboembolic disease in ART pregnancies 122 Table 20: Incidence of maternal mortality in ART pregnancies 126 Table 21: Incidence of maternal hospitalisation in ART pregnancies 128 Table 22: Incidence of ICU admission in ART pregnancies 130 Table 23a: Incidence of postpartum depression in ART pregnancies 131 Table 23b: Risk factors for postpartum depression in ART pregnancies 133 Table 24: Incidence of long term maternal morbidity in ART pregnancies 134 6 MATERNAL, PREGNANCY (...) with a non-ART pregnancy. The risk of thromboembolic disease is significantly increased in the first gestational trimester after ART. Despite having increased risk for being small for gestational age and having low birth weight, the long-term health outcomes of children born after ART in terms of neurodevelopment, cognitive function and physical growth appear to be comparable with spontaneously conceived children. However, a small increase in congenital abnormalities after ART compared to the general

2015 Sax Institute Evidence Check

39. The risk of venous thromboembolism in women with inflammatory bowel diseases during pregnancy and the postpartum period: protocol for systematic review and meta-analysis

The risk of venous thromboembolism in women with inflammatory bowel diseases during pregnancy and the postpartum period: protocol for systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (...) no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how subgroup variables are stratified etc. In order to assess

2017 PROSPERO

40. Venous Thromboembolism: Duration of Treatment

THROMBOSIS CANADA CLINICAL GUIDES: ? Cancer and Thrombosis ? Deep Vein Thrombosis (DVT): Treatment ? Pediatric Thrombosis ? Pregnancy: Venous Thromboembolism Treatment ? Pulmonary Embolism (PE): Treatment © 2015 Thrombosis Canada Page 5 of 5 REFERENCES: Kearon C, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-494S. Kearon C, Akl EA (...) Venous Thromboembolism: Duration of Treatment © 2015 Thrombosis Canada Page 1 of 5 VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE appear to fall into two categories: 1) Recurrences may be due to reactivation and extension of the original thrombosis. This risk is very high when patients first present with acute thrombosis; the risk decreases

2015 Thrombosis Interest Group of Canada

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>